Atea Pharmaceuticals
Late-stage clinical biopharmaceutical company focused on discovery, development and commercialization of orally available, direct-acting antiviral small molecules targeting single-stranded RNA viruses, with active programs in hepatitis C (HCV) and hepatitis E (HEV).
Industries
Nr. of Employees
medium (51-250)
Atea Pharmaceuticals
Boston, Massachusetts, United States
Patents
Products
Regimen of bemnifosbuvir plus ruzasvir (oral combination) for HCV
Orally administered fixed-dose combination regimen evaluated in global Phase 2 and Phase 3 trials for chronic hepatitis C; designed as an 8-week (non-cirrhotic) or 12-week (compensated cirrhosis) regimen with a profile aimed at low drug–drug interaction risk and no food effect.
Orally available nucleos(t)ide antiviral candidates (platform)
A platform of proprietary purine nucleos(t)ide prodrugs designed to inhibit viral RNA polymerases and enable mono- and combination regimens for ssRNA viruses.
Oral antiviral candidate programs for HEV and other ssRNA viruses
Development-stage oral small-molecule programs targeting hepatitis E virus and other single-stranded RNA viruses.
Regimen of bemnifosbuvir plus ruzasvir (oral combination) for HCV
Orally administered fixed-dose combination regimen evaluated in global Phase 2 and Phase 3 trials for chronic hepatitis C; designed as an 8-week (non-cirrhotic) or 12-week (compensated cirrhosis) regimen with a profile aimed at low drug–drug interaction risk and no food effect.
Orally available nucleos(t)ide antiviral candidates (platform)
A platform of proprietary purine nucleos(t)ide prodrugs designed to inhibit viral RNA polymerases and enable mono- and combination regimens for ssRNA viruses.
Oral antiviral candidate programs for HEV and other ssRNA viruses
Development-stage oral small-molecule programs targeting hepatitis E virus and other single-stranded RNA viruses.
Services
End-to-end clinical development services from discovery-stage R&D through late-stage clinical trials and preparation for commercialization focused on oral small-molecule antivirals.
End-to-end clinical development services from discovery-stage R&D through late-stage clinical trials and preparation for commercialization focused on oral small-molecule antivirals.
Expertise Areas
- Clinical trial management
- Antiviral drug discovery (nucleoside/nucleotide prodrugs)
- Virology and resistance profiling
- Pharmacokinetics and DDI assessment
Key Technologies
- Nucleos(t)ide prodrug chemistry
- RNA polymerase inhibition
- NS5A inhibition
- In vitro replicon antiviral assays
News & Updates
C-BEYOND, a North American Phase 3 trial comparing the bemnifosbuvir/ruzasvir regimen to a standard comparator, achieved its primary and secondary endpoints (July 2026); mITT SVR rates reported and statistical non-inferiority met.
IND clearance reported for an antiviral candidate with accompanying Series D financing (2020), supporting regulatory and development capabilities.
C-BEYOND, a North American Phase 3 trial comparing the bemnifosbuvir/ruzasvir regimen to a standard comparator, achieved its primary and secondary endpoints (July 2026); mITT SVR rates reported and statistical non-inferiority met.
IND clearance reported for an antiviral candidate with accompanying Series D financing (2020), supporting regulatory and development capabilities.